CN110183515B - 一种用于ptp1b检测的多肽及包含该多肽的荧光探针 - Google Patents
一种用于ptp1b检测的多肽及包含该多肽的荧光探针 Download PDFInfo
- Publication number
- CN110183515B CN110183515B CN201910348688.5A CN201910348688A CN110183515B CN 110183515 B CN110183515 B CN 110183515B CN 201910348688 A CN201910348688 A CN 201910348688A CN 110183515 B CN110183515 B CN 110183515B
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- fluorescent probe
- ptp1b
- compound
- aggregation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000007850 fluorescent dye Substances 0.000 title claims abstract description 70
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 41
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 41
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 41
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 title abstract description 39
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 title abstract description 38
- 238000001514 detection method Methods 0.000 title description 17
- 230000002776 aggregation Effects 0.000 claims abstract description 16
- 238000004220 aggregation Methods 0.000 claims abstract description 16
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000004472 Lysine Substances 0.000 claims abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical class CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- NPFYZDNDJHZQKY-UHFFFAOYSA-N 4-Hydroxybenzophenone Chemical compound C1=CC(O)=CC=C1C(=O)C1=CC=CC=C1 NPFYZDNDJHZQKY-UHFFFAOYSA-N 0.000 claims description 8
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 8
- 238000003786 synthesis reaction Methods 0.000 claims description 8
- 229940126062 Compound A Drugs 0.000 claims description 7
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 7
- 239000000523 sample Substances 0.000 claims description 7
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 6
- 239000007790 solid phase Substances 0.000 claims description 6
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 claims description 4
- 239000012965 benzophenone Substances 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- JLZUZNKTTIRERF-UHFFFAOYSA-N tetraphenylethylene Chemical group C1=CC=CC=C1C(C=1C=CC=CC=1)=C(C=1C=CC=CC=1)C1=CC=CC=C1 JLZUZNKTTIRERF-UHFFFAOYSA-N 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 238000010521 absorption reaction Methods 0.000 abstract description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract description 3
- 229910019142 PO4 Inorganic materials 0.000 abstract description 2
- 150000001413 amino acids Chemical group 0.000 abstract description 2
- 238000007877 drug screening Methods 0.000 abstract description 2
- 239000010452 phosphate Substances 0.000 abstract description 2
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical class OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 abstract description 2
- 239000004474 valine Substances 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 239000003801 protein tyrosine phosphatase 1B inhibitor Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 102100028516 Receptor-type tyrosine-protein phosphatase U Human genes 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 238000002189 fluorescence spectrum Methods 0.000 description 3
- -1 hydrogen ions Chemical class 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000003746 Insulin Receptor Human genes 0.000 description 2
- 108010001127 Insulin Receptor Proteins 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- 229910020700 Na3VO4 Inorganic materials 0.000 description 2
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 2
- 241000907663 Siproeta stelenes Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 239000003593 chromogenic compound Substances 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical group N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000005572 Cathepsin A Human genes 0.000 description 1
- 108010059081 Cathepsin A Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000006503 Janus Kinase 2 Human genes 0.000 description 1
- 108010019437 Janus Kinase 2 Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- ODUQLUADRKMHOZ-JYJNAYRXSA-N Lys-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N)O ODUQLUADRKMHOZ-JYJNAYRXSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- PMHLLBKTDHQMCY-ULQDDVLXSA-N Tyr-Lys-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O PMHLLBKTDHQMCY-ULQDDVLXSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000004155 insulin signaling pathway Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000006862 quantum yield reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1007—Non-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1003—Carbocyclic compounds
- C09K2211/1014—Carbocyclic compounds bridged by heteroatoms, e.g. N, P, Si or B
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Materials Engineering (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种能被PTP1B特异性识别的多肽以及包含该多肽的荧光探针,属于药物筛选与评价方法领域。该荧光探针由PTP1B特异性识别的多肽与聚集诱导发光分子连接而成,多肽的氨基酸序列为:赖氨酸‑谷氨酸‑磷酸化酪氨酸‑磷酸化酪氨酸‑赖氨酸‑缬氨酸,聚集诱导发光分子与多肽中的赖氨酸相连。由于多肽N端第三位和第四位含有磷酸化酪氨酸,使得PTP1B能对该多肽进行去磷酸化修饰。该荧光探针本身基本无荧光吸收,但当其失去酪氨酸上的磷酸根时,则会产生明显的荧光吸收,从而能对PTP1B活性进行特异性的检测。
Description
技术领域
本发明属于药物筛选与评价方法领域,具体涉及一种能被PTP1B特异性识别的多肽及包含该多肽的荧光探针。
背景技术
蛋白质酪氨酸磷酸化及去磷酸化是机体信号转导调控机制之一,受蛋白酪氨酸激酶和蛋白酪氨酸磷酸酶共同调控。蛋白酪氨酸磷酸酶1B(ProteinTyrosine Phosphatase-1B,PTP1B)是胞内型蛋白酪氨酸磷酸酶家族的一员,定位于细胞内质网,在肝脏、肌肉、脑、脂肪等组织广泛表达。研究表明,PTP1B是瘦素信号通路及胰岛素信号通路共同的负性调控因子。PTP1B通过使胰岛素受体、胰岛素受体底物以及Janus激酶2酪氨酸去磷酸化,阻断胰岛素和瘦素信号的传递。因此PTP1B抑制剂的开发在糖尿病治疗中具有广泛的应用前景。
目前常用的PTP1B抑制剂筛选方法主要有以对硝基苯磷酸酯(p-npp)为底物的发色底物法和通过磷酸根离子检测的孔雀石绿-钼酸盐分光光度法。但发色底物法背景干扰大,易受化合物结构影响;孔雀石绿-钼酸盐分光光度法对检测环境要求高,且无法直接检测PTP1B活性。
近年来,具有聚集诱导发光(Aggregation-induced emission,AIE)效应的荧光探针运用愈加广泛。这类探针可有效地避免传统荧光材料存在的聚集态荧光减弱甚至猝灭的现象,为设计高荧光量子产率的固态材料提供了一种新思路。
目前已报道了多种可用于酶活性检测的AIE型分子探针。例如专利申请号为201410250272.7的专利文献公开了一种用于碱性磷酸酶活性的荧光检测方法;专利申请号为201510108446.0的专利文献包含了一种具有聚集诱导发光特性的荧光探针及其制备方法和应用;专利申请号为201510507259.X的专利文献报道了一种用于DPP-4检测的多肽及包含该多肽的荧光探针。
因此,如何有效将AIE荧光探针技术用于PTP1B活性检测及PTP1B抑制剂筛选是本领域技术人员需要解决的问题。
发明内容
本发明的目的在于提供一种能被PTP1B特异性识别的多肽以及包含该多肽的荧光探针,利用该荧光探针可以特异性识别PTP1B并对其进行活性检测。
为实现上述目的,本发明采用如下技术方案:
一种多肽,所述多肽的氨基酸序列为:KEpYpYKV,其中p为磷酸化基团。由于多肽N端-第三位和第四位含有磷酸化酪氨酸,使得PTP1B能对该多肽进行去磷酸化修饰。
本发明还提供了一种具有聚集诱导发光特性的荧光探针,由上述多肽与聚集诱导发光分子连接而成,所述聚集诱导发光分子与所述多肽中N端第一位的赖氨酸相连。
本发明的荧光探针以聚集诱导发光分子为母核,连接亲水性的多肽,从而形成能特异性检测PTP1B的荧光探针。该荧光探针本身荧光很弱,但当其失去酪氨酸上的磷酸根时,则会产生明显的荧光吸收,从而能对PTP1B活性进行特异性的检测。
作为优选,所述聚集诱导发光分子包含由至少一个四苯乙烯分子构成的基本骨架。当基本骨架中含有多个四苯乙烯分子时,多个四苯乙烯分子之间通过分子间相互作用聚集。
作为优选,所述荧光探针的结构式如式(Ⅰ)所示:
本发明还提供了一种所述荧光探针的制备方法,包括以下步骤:
(1)通过固相多肽合成反应合成上述的多肽;
(2)以4-羟基二苯酮和二苯酮为原料制备化合物A:
具体地,步骤(2)包括:4-羟基二苯酮与二苯酮以四氢呋喃为溶剂在锌粉与四氯化钛催化下加热回流(85℃)发生麦克默里反应,经硅胶色谱分离制备得到化合物A。
(3)在碳酸盐存在下,利用卤代乙酸乙酯与化合物A进行取代反应,获得化合物B:
碳酸盐作为催化剂夺取化合物A酚羟基上的氢离子,以便使该氢离子能更快更容易地与卤代乙酸乙酯反应,若缺失碳酸盐,反应将会进行得十分缓慢。
作为优选,碳酸盐可选用碳酸钾或碳酸钠。
作为优选,化合物A、卤代乙酸乙酯、碳酸盐的摩尔比为1:1.2~1.4:1.2~1.4,在100~120℃之间回流24h进行取代反应。
(4)对化合物B进行还原获得化合物C:
作为优选,利用氢氧化钠、氢氧化钾或氢氧化锂等强碱对化合物C进行还原。
反应时,将化合物B先溶于四氢呋喃中制成B溶液(浓度为0.074M~0.082M),强碱先溶于水中制成强碱溶液(浓度为3.6M~4.0M),然后B溶液与强碱溶液在四氢呋喃环境下混合反应,混合比例优选为2.2~2.3:1(v/v)。
(5)利用步骤(1)所述的多肽与化合物C进行固相多肽合成反应,获得如式(Ⅰ)的荧光探针。
化合物C中的羧基与多肽中赖氨酸的氨基发生脱水缩合反应,获得本发明的荧光探针。
本发明还提供了所述荧光探针在PTP1B活性检测中的应用。
本发明还提供了所述荧光探针在PTP1B抑制剂筛选中的应用。
与现有技术相比,本发明的有益效果为:
本发明的荧光探针能够被PTP1B特异性地识别,PTP1B能改变荧光探针中磷酸化酪氨酸的磷酸化修饰,从而使本身基本无荧光吸收的荧光探针在480nm下产生明显的荧光吸收,实现对PTP1B活性的特异性检测,还能进一步用于筛选PTP1B抑制剂。
附图说明
图1为本发明一种具有聚集诱导发光特性的荧光探针的合成流程图。
图2荧光探针和荧光探针与酶反应后产物的荧光光谱分析结果图,其中PTP1B(+)表示含0.6μg/mL PTP1B。
图3为HepG2细胞蛋白与荧光探针反应量效关系图,其中,荧光增长率表示(样品荧光值-本底荧光值)/本底荧光值。
图4为本发明荧光探针检测PTP1B的原理图。
图5为抑制剂浓度与其对PTP1B抑制效应的量效关系图。
图6为不同浓度抑制剂孵育后HepG2细胞蛋白与荧光探针反应的荧光增长率。
图7为荧光探针对PTP1B的检测灵敏度考察结果。
图8为与其他蛋白相比,荧光探针对PTP1B检测特异性考察结果。
图9为荧光探针的细胞毒性测试结果。
具体实施方式
下面结合附图和具体实施方式对本发明作进一步详细说明。
实施例1具有AIE特性的荧光探针合成
本实施例提供一种具有AIE特性的荧光探针的合成方法,其合成流程如图1所示,包括:
(1)通过固相多肽合成反应单独合成多肽链,多肽链的序列为赖氨酸-谷氨酸-磷酸化酪氨酸-磷酸化酪氨酸-赖氨酸-缬氨酸;
(2)将4-羟基二苯酮(1.9g,10mmol)与二苯酮(2.2g,12mmol)与锌粉(2.9g,44mmol)加入250ml三口烧瓶中,抽气,通氮气,重复三次;加入80ml THF(四氢呋喃),0℃冰水浴30min;在冰水浴下滴加四氯化钛(2.4ml,22mmol),回流过夜,旋干;加入适量二氯甲烷和稀盐酸进行萃取,取下层有机层,利用无水硫酸镁进行干燥,过滤,旋干,过硅胶柱色谱,先用石油醚:乙酸乙酯=20:1溶剂冲洗,再用石油醚:乙酸乙酯=8:1溶剂冲洗,收集8:1冲洗下来的部分,旋干,得到化合物A(1.0g);
(3)取化合物A(1.0g)加入圆底烧瓶,再加入溴乙酸乙酯0.4ml与碳酸钾0.5g,再加入乙腈,搅拌,升温至110℃,回流24h,过滤,旋干溶剂,过硅胶柱色谱,先用石油醚冲洗,再用石油醚:乙酸乙酯=20:1溶剂冲洗;收集20:1冲洗下来的部分,旋干,得到化合物B(约0.7g);
(4)向化合物B中加入THF 28ml,加入氢氧化钠2g(事先用12ml水溶解),反应24h,旋干THF,用二氯甲烷溶解,再加入稀盐酸,萃取,取有机相,旋干,得到化合物C(0.4g,TPE-COOH);
(5)将多肽链的赖氨酸N端氨基与化合物C进行固相多肽合成反应,得到化合物D即本实施例的荧光探针TPE-KEpYpYKV。
实施例2荧光探针TPE-KEpYpYKV在PTP1B活性检测中的应用
(1)荧光探针和荧光探针与酶反应后产物的荧光光谱分析。
样品组1:加入50μL浓度为100μM的荧光探针TPE-KEpYpYKV;
样品组2:加入1.5μL浓度为40μg/mL的PTP1B、50μL浓度为100μM的荧光探针TPE-KEpYpYKV;
两个样品组以缓冲液Tris-HCl(10mM,pH 7.5,含50mMNa+、2mMDTT)补齐至100μL,在37℃孵育下反应15min。反应结束后采用Tecan酶标仪测量320nm激发下,400nm到600nm的荧光光谱。
检测结果见图2。
由图2可见,合成的荧光探针TPE-KEpYpYKV在400-600nm范围内基本无荧光吸收,TPE-KEpYpYKV与PTP1B反应后在480nm处由于聚合诱导发光效应产生明显的荧光吸收。这是因为荧光探针TPE-KEpYpYKV本身基本无荧光吸收,但当PTP1B加入后,PTP1B去掉酪氨酸上的磷酸化修饰,使得荧光探针发生聚集,产生了荧光吸收。
(2)荧光探针TPE-KEpYpYKV在HepG2细胞蛋白PTP1B活性检测中的应用
取50μL浓度为100μM的荧光探针TPE-KEpYpYKV,加入不同浓度HepG2细胞蛋白提取液(终浓度分别为0.02,0.11,0.22,0.45,0.89,1.34mg/mL),以缓冲液Tris-HCl(10mM,pH7.5,含50mMNa+、2mMDTT)补齐至100μL,37℃孵育15min后用Tecan酶标仪测量,设定Ex为320nm(±5nm),Em为480nm(±5nm)。
检测结果见图3。
由图3可见,在荧光探针TPE-KEpYpYKV浓度不变的情况下,随着HepG2细胞蛋白浓度增加,体系的荧光增长率也随着提高。
实施例3荧光探针TPE-KEpYpYKV在筛选PTP1B抑制剂中的应用
(1)荧光探针TPE-KEpYpYKV在筛选PTP1B抑制剂中的应用
取50μL浓度为100μM的荧光探针TPE-KEpYpYKV,加入1.5μL浓度为40μg/mL的PTP1B和一定体积不同浓度Na3VO4母液(使得Na3VO4终浓度为0.5,1,5,25,125,250,500μM),以缓冲液Tris-HCl(10mM,pH 7.5,含50mMNa+、2mMDTT)补齐至100μL,37℃孵育15min后用Tecan酶标仪测量,设定Ex为320nm(±5nm),Em为480nm(±5nm)。
检测结果见图5。
由图5可见,随着Na3VO4浓度的提高,Na3VO4对PTP1B的抑制效应也逐渐增加;表明荧光探针TPE-KEpYpYKV的荧光增长率能较好地反映抑制剂对PTP1B的抑制作用,可用于PTP1B抑制剂的筛选。
(2)荧光探针TPE-KEpYpYKV在基于细胞蛋白提取液的PTP1B抑制剂筛选中的应用
取50μL浓度为100μM的荧光探针TPE-KEpYpYKV,分别加入0,10,20,50μMNa3VO4孵育后HepG2细胞蛋白(终浓度0.89mg/mL),以缓冲液Tris-HCl(10mM,pH 7.5,含50mMNa+、2mMDTT)补齐至100μL,37℃孵育15min后用Tecan酶标仪测量,设定Ex为320nm(±5nm),Em为480nm(±5nm)。
检测结果见图6。
由图6可见,在细胞蛋白层面上,荧光探针TPE-KEpYpYKV的荧光增长率能够较好地反映PTP1B的抑制。
实施例4荧光探针TPE-KEpYpYKV对PTP1B的检测灵敏度考察
取50μL浓度为100μM的荧光探针TPE-KEpYpYKV,加入不同浓度PTP1B(终浓度分别为0.05,0.1,0.2,0.3,0.4,0.6,0.8,1.0μg/mL),以缓冲液Tris-HCl(10mM,pH 7.5,含50mMNa+、2mMDTT)补齐至100μL,37℃孵育15min后用Tecan酶标仪测量,设定Ex为320nm(±5nm),Em为480nm(±5nm)。
检测结果见图7。
由图7可见,荧光探针TPE-KEpYpYKV对PTP1B的线性检测范围为0.1-0.4μg/mL,检测限为0.05μg/mL。
实施例5荧光探针TPE-KEpYpYKV对PTP1B的检测特异性考察
取50μL浓度为100μM的荧光探针TPE-KEpYpYKV,分别加入终浓度均为0.6μg/mL的PTP1B、牛血清蛋白、α-糖苷酶、脂肪酶、胰蛋白酶、糜蛋白酶、羧肽酶Y,以缓冲液Tris-HCl(10mM,pH 7.5,含50mMNa+、2mMDTT)补齐至100μL,37℃孵育15min后用Tecan酶标仪测量,设定Ex为320nm(±5nm),Em为480nm(±5nm)。
检测结果见图8。
由图8可见,PTP1B组的荧光增长率较高,其他组的荧光增长率均非常弱,表明荧光探针TPE-KEpYpYKV仅能被PTP1B特异性识别,对PTP1B具有较强的检测特异性。
实施例6荧光探针TPE-KEpYpYKV的细胞毒性测试
取TPE-KEpYpYKV(终浓度分别为100和200μM)加入到离体培养HepG2中,孵育24小时后,用MTT法检测细胞活性。
检测结果见图9。
由图9可见,当荧光探针TPE-KEpYpYKV浓度小于200μM时,24小时内对细胞无毒性。
序列表
<110> 浙江中医药大学
<120> 一种用于PTP1B检测的多肽及包含该多肽的荧光探针
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 6
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Lys Glu Tyr Tyr Lys Val
1 5
Claims (6)
1.一种多肽,其特征在于,所述多肽的氨基酸序列为:KEpYpYKV,其中p为磷酸化基团。
2.一种具有聚集诱导发光特性的荧光探针,其特征在于,由权利要求1所述的多肽与聚集诱导发光分子连接而成,所述聚集诱导发光分子与所述多肽中的赖氨酸相连。
3.如权利要求2所述的具有聚集诱导发光特性的荧光探针,其特征在于,所述聚集诱导发光分子包含由至少一个四苯乙烯分子构成的基本骨架。
6.如权利要求5所述的具有聚集诱导发光特性的荧光探针的制备方法,其特征在于,步骤(4)中,利用强碱对化合物B进行还原。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910348688.5A CN110183515B (zh) | 2019-04-28 | 2019-04-28 | 一种用于ptp1b检测的多肽及包含该多肽的荧光探针 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910348688.5A CN110183515B (zh) | 2019-04-28 | 2019-04-28 | 一种用于ptp1b检测的多肽及包含该多肽的荧光探针 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110183515A CN110183515A (zh) | 2019-08-30 |
CN110183515B true CN110183515B (zh) | 2020-09-29 |
Family
ID=67715236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910348688.5A Active CN110183515B (zh) | 2019-04-28 | 2019-04-28 | 一种用于ptp1b检测的多肽及包含该多肽的荧光探针 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110183515B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115417922A (zh) * | 2020-12-21 | 2022-12-02 | 青岛科技大学 | 一种PTP1B多肽抑制剂BimBH3-12-F12A及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010151495A2 (en) * | 2009-06-26 | 2010-12-29 | University Of Florida Research Foundation Inc. | Materials and methods for treating and preventing viral infections |
CN104749377A (zh) * | 2015-03-12 | 2015-07-01 | 浙江大学 | 一种具有聚集诱导发光特性的荧光探针及其制备方法和应用 |
-
2019
- 2019-04-28 CN CN201910348688.5A patent/CN110183515B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010151495A2 (en) * | 2009-06-26 | 2010-12-29 | University Of Florida Research Foundation Inc. | Materials and methods for treating and preventing viral infections |
CN104749377A (zh) * | 2015-03-12 | 2015-07-01 | 浙江大学 | 一种具有聚集诱导发光特性的荧光探针及其制备方法和应用 |
Non-Patent Citations (2)
Title |
---|
PTP1B: A simple enzyme for a complex world;Matthew Feldhammer 等;《Critical Reviews in Biochemistry and Molecular Biology》;20130723;第48卷(第5期);第430-445页 * |
基于荧光探针的消渴安中DPP-4抑制剂的筛选与鉴定;吴雪莉 等;《中国中药杂志》;20160401;第41卷(第7期);第1241-1245页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110183515A (zh) | 2019-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106706591B (zh) | 一种可逆纳米卟啉荧光传感器识别定量手性氨基酸方法 | |
CN110172337B (zh) | 一种苯并噻唑衍生物荧光探针及其制备方法和应用 | |
CN104341346B (zh) | 一种基于白蛋白假酯酶水解反应的特异性荧光探针及应用 | |
CN110376176A (zh) | 双掺杂金属有机骨架复合物比率荧光黄岑苷探针制备方法 | |
CN106841128B (zh) | 一类检测人血清白蛋白的高特异性荧光探针的应用 | |
CN105524055A (zh) | 一种能够区分半胱氨酸/同型半胱氨酸和谷胱甘肽荧光探针的制备与应用 | |
CN109836394A (zh) | 一种用于识别硫化氢的近红外荧光探针及其制备方法和应用 | |
Qiu et al. | A rapid-response near-infrared fluorescent probe with a large Stokes shift for senescence-associated β-galactosidase activity detection and imaging of senescent cells | |
CN108659099B (zh) | 一种用于血管紧张素转化酶活性检测的质谱探针及其应用 | |
CN106814153A (zh) | 基于凝血酶和凝血因子的双靶点抗凝活性物质的液相色谱‑质谱筛选方法 | |
CN105136755A (zh) | 一种用于检测红霉素的荧光偏振免疫分析方法 | |
CN110183515B (zh) | 一种用于ptp1b检测的多肽及包含该多肽的荧光探针 | |
CN111285836A (zh) | 一种近红外荧光探针的制备和应用 | |
CN109001471A (zh) | 游离人绒毛膜促性腺激素β亚单位化学发光检测试剂盒及其制备方法和使用方法 | |
CN117964548A (zh) | 一种用于筛选单胺氧化酶b抑制剂的荧光探针的制备方法及应用 | |
Dong et al. | A “traffic light” signal ratiometric fluorescence sensor for highly sensitive and selective detection of dopamine | |
CN111233928B (zh) | 一种香豆素衍生物Mito-Cys及其制备方法和应用 | |
CN111233876B (zh) | 一种检测硫化氢的荧光探针及其制备方法和应用 | |
CN113620997A (zh) | 一种环金属铱配合物比率型一氧化碳荧光探针的制备及应用 | |
Suzuki | Development of a fluorescent peptide for the highly sensitive and selective detection of oxytocin | |
CN110642857B (zh) | 一种用于检测粘度和pH的双功能荧光探针及其制备与应用 | |
CN105928912B (zh) | 一种肝素的检测方法 | |
CN110894193B (zh) | 一种新型荧光探针的合成及在检测半胱氨酸中的应用 | |
Wang et al. | Rational design of a HA-AuNPs@ AIED nanoassembly for activatable fluorescence detection of HAase and imaging in tumor cells | |
Jiang et al. | “Zero” Intrinsic Fluorescence Sensing‐Platforms Enable Ultrasensitive Whole Blood Diagnosis and In Vivo Imaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |